Site search
2816 results for '' found
PHASE IB OPEN LABEL BASKET TRIAL OF RAY121 TO INHIBIT CLASSICAL COMPLEMENT PATHWAY IN IMMUNOLOGICAL DISEASES [RAINBOW TRIAL] (NCT06371417)
PHASE IB OPEN LABEL BASKET TRIAL OF RAY121 TO INHIBIT CLASSICAL COMPLEMENT PATHWAY IN IMMUNOLOGICAL DISEASES [RAINBOW TRIAL] (NCT06371417)
/research/clinical-trials/find-clinical-trials/phase-ib-open-label-basket-trial-of-ray121-to-inhibit-classical-complement-pathway-in-immunological-diseases-rainbow-trial-nct06371417
A randomised trial of most closely HLA-matched third-party donor-derived virus-specific cytotoxic T-lymphocytes in patients with untreated viral infection post-allogeneic stem cell transplantatio
A randomised trial of most closely HLA-matched third-party donor-derived virus-specific cytotoxic T-lymphocytes in patients with untreated viral infection post-allogeneic stem cell transplantatio
/research/clinical-trials/find-clinical-trials/a-randomised-trial-of-most-closely-hla-matched-third-party-donor-derived-virus-specific-cytotoxic-t-lymphocytes-in-patients-with-untreated-viral-infection-post-allogeneic-stem-cell-transplantatio
A Phase 3 Trial of Fianlimab (anti-LAG-3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-risk Melanoma (NCT05608291)
A Phase 3 Trial of Fianlimab (anti-LAG-3) and Cemiplimab versus Pembrolizumab in the Adjuvant Setting in Patients with Completely Resected High-risk Melanoma (NCT05608291)
/research/clinical-trials/find-clinical-trials/a-phase-3-trial-of-fianlimab-anti-lag-3-and-cemiplimab-versus-pembrolizumab-in-the-adjuvant-setting-in-patients-with-completely-resected-high-risk-melanoma-nct05608291
A Phase 3 Trial of Fianlimab (REGN3767, anti-Lag-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma (NCT05352672)
A Phase 3 Trial of Fianlimab (REGN3767, anti-Lag-3) + Cemiplimab versus Pembrolizumab in Patients with Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma (NCT05352672)
/research/clinical-trials/find-clinical-trials/a-phase-3-trial-of-fianlimab-regn3767-anti-lag-3-cemiplimab-versus-pembrolizumab-in-patients-with-previously-untreated-unresectable-locally-advanced-or-metastatic-melanoma-nct05352672
Assessing Benefits of Near Infrared Autofluorescence Detection for Identifying Parathyroid Glands during Endocrine Surgery (NCT05022667)
Assessing Benefits of Near Infrared Autofluorescence Detection for Identifying Parathyroid Glands during Endocrine Surgery (NCT05022667)
/research/clinical-trials/find-clinical-trials/assessing-benefits-of-near-infrared-autofluorescence-detection-for-identifying-parathyroid-glands-during-endocrine-surgery-nct05022667
A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera (PTG-300-11) (NCT05210790)
A Phase 3 Study of the Hepcidin Mimetic Rusfertide (PTG-300) in Patients with Polycythemia Vera (PTG-300-11) (NCT05210790)
/research/clinical-trials/find-clinical-trials/a-phase-3-study-of-the-hepcidin-mimetic-rusfertide-ptg-300-in-patients-with-polycythemia-vera-ptg-300-11-nct05210790
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Par
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Par
/research/clinical-trials/find-clinical-trials/a-phase-3-multicenter-randomized-double-blind-placebo-controlled-and-ustekinumab-active-comparator-controlled-study-to-evaluate-the-efficacy-and-safety-of-jnj-77242113-for-the-treatment-of-par
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 in Participants with Relapsed/Refractory Hematologic Malignancies (NCT05665530)
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 in Participants with Relapsed/Refractory Hematologic Malignancies (NCT05665530)
/research/clinical-trials/find-clinical-trials/a-phase-1-open-label-multi-center-safety-and-efficacy-study-of-prt2527-in-participants-with-relapsed-refractory-hematologic-malignancies-nct05665530
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab in Participants
/research/clinical-trials/find-clinical-trials/a-phase-iii-multicentre-randomised-double-blind-chronic-dosing-parallel-group-placebo-controlled-extension-study-to-evaluate-the-long-term-efficacy-and-safety-of-tozorakimab-in-participants
A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared
A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK4527226 [AL101] Intravenous Infusion Compared
/research/clinical-trials/find-clinical-trials/a-phase-2-parallel-group-randomized-double-blind-placebo-controlled-3-arm-multicenter-treatment-study-to-evaluate-the-efficacy-and-safety-of-gsk4527226-al101-intravenous-infusion-compared